Effects of milrinone and butyrolactone-I on porcine oocyte meiotic progression and developmental competence.
Inappropriate coordination of oocyte nuclear and cytoplasmic maturation is thought to contribute to the poor efficiency of embryo production in vitro. With the aim of improving this coordination, the effects of milrinone, an inhibitor of type 3 phosphodiesterases, and butyrolactone-I, a selective inhibitor of cdc2 kinases, on porcine oocyte maturation were investigated. Oocytes recovered from slaughterhouse-derived ovaries of prepubertal animals were treated with the inhibitors for 24 h. At concentrations of 50 and 250 microm, milrinone reversibly inhibited meiotic progression in 57% and 71% of oocytes, respectively. The presence or absence of milrinone in the medium used to wash oocytes for 30 min did not alter the inhibitory effect of the 24 h treatment. At concentrations of 25 and 50 microm, butyrolactone-I inhibited meiotic progression in 61% and 66% of oocytes, respectively, but the effect was not fully reversible in the absence of follicle-stimulating hormone (FSH). The presence of FSH during the butyrolactone-I treatment period increased the ability of oocytes to subsequently complete meiosis at 44 h without changing the inhibitory effect at 24 h. Following in vitro fertilisation at 44 and 50 h, treatment with butyrolactone-I and milrinone, alone or in combination, did not alter embryo cleavage rate, blastocyst formation rate or blastocyst cell number. Despite the different actions of milrinone and butyrolactone-I, the present study demonstrates that these reagents inhibit meiotic progression to a similar extent in the presence of FSH while maintaining developmental competence in porcine oocytes.
Research Centre for Reproductive Health, Department of Obstetrics and Gynaecology, The University of Adelaide, The Queen Elizabeth Hospital, Woodville Road, Woodville, SA 5011, Australia. chris.grupen@adelaide.edu.au
Christopher G
CG
Grupen
Maggie
M
Fung
David T
DT
Armstrong
D015107:4-Butyrolactone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000818:Animals; D002467:Cell Nucleus / Q000187:drug effects; D003470:Culture Media; D004347:Drug Interactions; D005260:Female; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage; D066298:In Vitro Techniques; D008540:Meiosis / Q000187:drug effects; D020105:Milrinone / Q000008:administration & dosage*; D009865:Oocytes / Q000166:cytology / Q000187:drug effects* / Q000254:growth & development; D009866:Oogenesis / Q000187:drug effects; D034421:Sus scrofa
D003470:Culture Media; C082868:butyrolactone I; D005640:Follicle Stimulating Hormone; D020105:Milrinone; D015107:4-Butyrolactone